Background: Impressive in vitro research in rodents and computational modeling has uncovered the core mechanisms responsible for generating neuronal oscillations. In particular, GABAergic interneurons play a crucial role for synchronizing neural populations. Do these mechanistic principles apply to human oscillations associated with function? To address this, we recorded ongoing brain activity using magnetoencephalography (MEG) in healthy human subjects participating in a double-blind pharmacological study receiving placebo, 0.5 mg and 1.5 mg of lorazepam (LZP; a benzodiazepine upregulating GABAergic conductance). Participants performed a demanding visuospatial working memory (WM) task. Results: We found that occipital gamma power associated with WM recognition increased with LZP dosage. Importantly, the frequency of the gamma activity decreased with dosage, as predicted by models derived from the rat hippocampus. A regionally specific gamma increase correlated with the drugrelated performance decrease. Despite the system-wide pharmacological intervention, gamma power drug modulations were specific to visual cortex: sensorimotor gamma power and frequency during button presses remained unaffected. In contrast, occipital alpha power modulations during the delay interval decreased parametrically with drug dosage, predicting performance impairment. Consistent with alpha oscillations reflecting functional inhibition, LZP affected alpha power strongly in early visual regions not required for the task demonstrating a regional specific occipital impairment. Conclusions: GABAergic interneurons are strongly implicated in the generation of gamma and alpha oscillations in human occipital cortex where drug-induced power modulations predicted WM performance. Our findings bring us an important step closer to linking neuronal dynamics to behavior by embracing established animal models.
Introduction
The human ability to encode, maintain, and manipulate visual representations requires a strict temporal coordination of neuronal activity. Numerous investigations point to oscillatory brain activity playing an important role in cognition [1] , including one of the most important cognitive operations: working memory (WM). Impressive in vitro animal models have shown that GABAergic interneurons are intimately involved in the mechanisms producing neuronal synchronization, especially the gamma band (30-100 Hz) [2, 3] . This notion is supported by exhaustive experimental work in rat hippocampus slices demonstrating that pharmacological GABAergic enhancement increases the amplitude of spontaneous gamma oscillations while decreasing the frequency [4] [5] [6] [7] . These gamma modulations can be mechanistically explained by a prolongation of the time course of inhibitory postsynaptic currents (IPSC) caused by the GABAergic enhancement. As a consequence, the inhibitory period, which determines the gamma frequency, increases. Although these oscillatory mechanisms have been extensively investigated in animal models, such as brain-slice preparations of the rat hippocampus, the link to function is highly limited. It is not known whether the same physiological mechanisms apply to human brain oscillations and, most importantly, whether they support human WM operations.
Visuospatial WM requires the encoding and retention of neuronal representations as well as recognition. Neuronal synchronization in the gamma band has been associated with the processing of visual stimuli and attention in monkeys and humans [8] . Specifically, gamma power and coherence increase with the spatial allocation of attention ( [9, 10] , but see [11] ) and are predictive of response times to visual stimuli [10] . On the other hand, during rest, GABAergic neurotransmission is implicated in the generation of oscillatory activity in the alpha band (8) (9) (10) (11) (12) (13) (14) Hz) in animals [12] and humans [13, 14] . Functionally, the alpha band has been linked to the allocation of computational resources by inhibiting regions not required for a given task [15, 16] .
In short, recent evidence supports the notion that gamma band activity is involved in active processing, whereas alpha oscillations reflect the allocation of neuronal resources by functional inhibition. In the present study, we have used magnetoencephalography (MEG) to investigate whether the animal models for gamma and alpha oscillations generalize to humans. Here, by pharmacologically manipulating the GABAergic efficacy with lorazepam (LZP), we ask whether inhibitory interneurons are involved in producing the WM-related gamma and alpha band activity and its consequences for behavior.
Results
We performed a double-blind randomized crossover design in which healthy participants received either placebo or LZP at two different doses (0.5 mg and 1.5 mg). LZP is a common benzodiazepine that binds allosterically to GABA A receptors and enhances chloride conductance by increasing its channel-opening frequency [17] . We used MEG to measure the ongoing brain activity while subjects performed a delayed match-to-sample visuospatial WM task [18] (Figures 1A and  1B) . Each trial started by presenting a centrally presented visual cue for 1.5 s. The task was to encode the sample array composed of colored squares presented in the cued hemifield while maintaining central fixation. After a 1.5 s delay interval, a probe array was presented, and participants had to indicate whether it matched the sample array or not. Prior to the MEG experiment, we had assessed the participants WM capacity.
This allowed us to have the participants perform with accuracy close to 75%, matching task difficulty (for details, see Supplemental Experimental Procedures available online).
Importantly, head position showed no systematic differences over the three experimental sessions (F 2, 48 = 0.69, p = 0.45; Figure S1 ; see Supplemental Experimental Procedures and [19] ). Although performance decreased with LZP, (see below), it did not influence performance in a control task (WM load 1, Figure S2 ) or drowsiness as measured by subjective questionnaire tests as a function of dosage (visual analog scales or the placebo-drug scale, Figure S3 ).
LZP Decreases Performance and WM Capacity
We first set out to investigate the behavioral consequences of LZP. Performance was assessed by considering K span (a measure of the effective memory span when considering hits and false alarm rates) and accuracy ( Figure 1C ). Regarding the K span , we found a strong main effect of drug (F 2, 48 = 9.77, p < 5 3 10 24 ; placebo = 0.5 mg LZP: t 24 = 1.73, p = 0.09; placebo > 1.5 mg LZP: t 24 = 4.39, p < 0.001; 0.5 mg LZP > 1.5 mg LZP: t 24 = 2.7, p < 0.02; Figure 1D ), explained by a decrease in hit rate (F 2, 48 = 9.78, p < 5 3 10 24 ) without false alarm rate change with LZP (F 2, 48 = 1.14, p = 0.33; Figure 1D ). As expected, LZP resulted in an increase in reaction times (F 1.5, 35.6 = 6.16, p < 0.01; placebo = 0.5 mg LZP: t 24 = 20.02, p = 0.98; placebo < 1.5 mg LZP: t 24 = 22.43, p < 0.05; 0.5 mg LZP < 1.5 mg LZP: t 24 = 23.88, p < 0.005; Figure 1E ). Similarly, LZP decreased d prime without impact response bias (Figure S4 ). In conclusion, LZP produced a WM performance impairment accompanied by an increase in reaction times.
LZP Increases Stimulus-Induced Gamma Power
Here, we asked whether GABAergic neurotransmission plays a role in the generation of human gamma activity by characterizing how stimulus-induced gamma activity as measured by MEG is affected by LZP. First, we calculated the time-frequency representations (TFRs) of power in the gamma band . We observed strong stimulusinduced gamma activity over occipital sensors in response to the sample (0.1-0.35 s) and probe (1.75-2.15 s) periods in all drug conditions (Figures 2A-2C ). Using a beamformer approach, we localized the sources of the gamma activity to occipital cortex with maxima in primary visual cortex.
Next, we asked whether the stimulus-induced gamma band activity was modulated by LZP by considering a set of posterior sensors (marked sensors in Figure 2 topography plots; see Supplemental Experimental Procedures for sensor selection). We constructed pairwise scatterplots comparing the different drug conditions over participants ( Figure 2D ). Clearly, LZP increased the stimulus-induced gamma power during the probe period in most participants, as also confirmed by a Wilcoxon signed-rank test. Also, during the sample interval, the LZP resulted in an increase in stimulus-induced gamma power (F 2, 48 = 3.75, p < 0.05; placebo < 0.5 mg LZP: t 24 = 22.29, p < 0.05; placebo < 1.5 mg LZP: t 24 = 22.56, p < 0.05; 0.5 mg LZP = 1.5 mg LZP: t 24 = 20.89, p < 0.38; Figure 2E ).The same pattern was observed in the probe interval (F 2, 48 = 6.13, p < 0.005; placebo < 0.5 mg LZP: t 24 = 22.4, p < 0.05; placebo < 1.5 mg LZP: t 24 = 22.89, p < 0.05; 0.5 mg LZP = 1.5 mg LZP: t 24 = 21.87, p = 0.07; Figure 2F ). Finally, the gamma power in contralateral hemisphere was stronger in comparison with ipsilateral hemisphere, regardless of LZP dose for both the sample arrays ( Figure 2G ) and the probe arrays ( Figure 2H ). As control analysis, we tested whether there were systematic gamma power differences between the drug sessions in the baseline interval (20.5 s to 20.1 s), but this was not the case (F 1.1, 26.8 = 1.89, p = 0.18). Despite the strong stimulus-induced gamma power increase, the LZP dosage did not modulate the degree of Error bars show the SEM.
gamma band modulation as induced by the cue (F 2, 48 = 0.25, p = 0.77; Figure S5 ). In sum, we found that gamma power during sample and probe increased with LZP dosage. However, the cue-induced hemispheric lateralization in the gamma band did not systematically change with drug.
The Gamma Power that Increased with LZP Predicted Increased Reaction Times Do the changes in gamma power with LZP explain the changes in behavior? To explore this, we correlated the drug-related changes in gamma power with the drug-related changes in performance. When considering the gamma power in occipital sensors contralateral to the attended visual hemifield, we found a positive correlation with reaction times between 0.5 mg LZP and placebo (r spearman = 0.42, p < 0.05; Figure 2I ). No significant correlations were found between 1.5 mg LZP and reaction time (r spearman = 0.3, p = 0.14; Figure 2J ) or any other behavioral index. Further, we did not find an effect in sensors ipsilateral to the cued hemifield. Summarizing, the increase in reaction time with 0.5 mg LZP dosage (but not with 1.5 mg) was predicted by a drug-related increase of contralateral gamma power in response to the probe.
Gamma Frequency Decreased with LZP
Experiments on hippocampal slices have shown that an increase in inhibitory conductance by pharmacological GABAergic enhancement decreases gamma frequency [4] [5] [6] [7] . We sought to test whether this finding generalizes to the human visual stimulus-induced gamma response. To quantify potential frequency changes in the power spectra, we first computed the TFR of the relative change in stimulus-induced gamma during probe presentation ( Figure 3A ). We observed that the power in the gamma band shifted toward lower frequencies (<75 Hz) with LZP. This is also observed when averaging over the 1.8-1.95 s probe array interval ( Figure 3B ). To quantify this frequency shift, we calculated the ''center-ofmass'' index (see Supplemental Experimental Procedures) applied to the 50-100 Hz range around the peak in the probe interval defined above. A Wilcoxon signed-rank test revealed that 1.5 mg LZP significantly reduced the gamma frequency in comparison with placebo (z = 22.68, p < 0.01) and 0.5 mg LZP (z = 22.6, p < 0.01). We did not observe a difference between 0.5 mg LZP and placebo (z = 20.55, p = 0.58). We conclude that the dominant frequency in the gamma band frequency decreases with LZP dosage. As gamma frequency decreases with LZP, one might wonder whether individual gamma frequencies correlate with WM capacity or whether the reduction in WM capacity is predicted by the slowing of the gamma frequency. We addressed this by correlating the gamma frequency (center of mass) with the maximum WM capacity (K span ) measured during the behavioral experiment in session 1. There was no significant correlation between K span and gamma frequency in any of the sessions (placebo r spearman = 0.09, p = 0.64; 0.5 mg LZP r spearman = 0.07, p = 0.73; 1.5 mg LZP r spearman = 0.18, p = 0.37). Further, when comparing the drug sessions, there were no significant relationships between the WM capacity reduction and the gamma frequency slowing with neither 0.5 mg LZP (r spearman = 0.14, p = 0.50) nor 1.5 mg LZP (r spearman = 0.08, p = 0.71).
LZP Leaves Gamma Activity in Motor Cortex Unaffected
To further determine the brain region specificity of our pharmacological manipulation, we explored the oscillatory dynamics in sensorimotor cortex during the button-press response. Recent human studies have reported on gamma activity in motor cortical areas [20, 21] . To this end, we calculated the TFRs of power, which were time locked to participants' button presses. This revealed gamma activity at the time of the motor response. Contrary to visual areas, the motor-related gamma power was not affected by LZP (F 2, 48 = 0.78, p = 0.46; Figure 4 ). Likewise, absolute gamma power during baseline period (20.5 s to 20.3 s) was not statistically different (F 1.1, 28.5 = 0.85, p = 0.81), discarding the possibility that systematic changes during the premovement period could explain the null effect. These results demonstrate that the pharmacological manipulation specifically affected gamma band activity in the visual cortex. 
Modulation of Occipital Alpha Power Is Reduced by LZP
We then set out to examine how brain activity in the lower-frequency bands (<40 Hz) was modulated by LZP. TFRs of power were calculated for individual trials and then averaged with respect to spatial attention condition (left or right) for each MEG session separately. We first considered the modulation with respect to spatial attention. A modulation index (MI) was calculated as the normalized power difference between the attention left versus right trials [22] : MI = (power attention left 2 power attention right ) / (power attention left + power attention right ). Importantly, the same denominator for all drug sessions was used in the normalization (i.e., power attention left + power attention right from the placebo condition). As shown in Figure 5 , alpha band activity was strongly modulated by spatial attention throughout the task. It was reduced contralateral to the direction of attention while it increased relatively over the ipsilateral hemisphere ( Figures 5A-5C , left and right columns). Source reconstruction using a beamforming approach revealed that the alpha power was modulated mainly in occipital regions ( Figures 5A-5C, center column) .
To identify sensors of interest that showed oscillatory power modulations as a function of allocation of attention, we pooled all MEG sessions and conducted a cluster-based nonparametric permutation test applied to the cue period (21 s to 20.1 s) in the alpha band (9-13 Hz) (see Supplemental Experimental Procedures). For these sensor groups (see Figures 5A-5C , topographical plots, bold circles), we averaged the MI with attention over the left and the right hemisphere (absolute value) and tested the influence of LZP during the delay period (0.5-1.4 s). In addition, we constructed pairwise scatterplots comparing the different drug conditions over participants. These plots revealed that the alpha MI decreased with drug dosage in most participants, as confirmed by the Wilcoxon signed-rank test ( Figure 5D ). The parametric reduction in modulation with dosage was further confirmed by repeated-measures ANOVA (F 1.4, 34.3 = 11.95, p < 5 3 10 24 ; placebo > 0.5 mg LZP: t 24 = 2.9, p < 0.01; placebo > 1.5 mg LZP: t 24 = 3.84, p < 0.005; 0.5 mg LZP > 1.5 mg LZP: t 24 = 3.01, p < 0.01; Figure 5E ), with both hemispheres being affected by LZP in a nondifferent way. Similar statistical conclusions were found using within-session total power as a denominator (F 2, 48 = 6.35, p < 0.005). Complementarily, for each participant, we fitted regression lines to the alpha MI for each session using categorical values (1, 2, and 3) to represent LZP dosages. This resulted in negative slopes significantly different from zero (20.015 6 0.004; t 24 = 23.84, p < 0.001), supporting the notion that the decrease in alpha power with LZP was highly robust.
In short, we found that posterior alpha band activity was modulated as a function of spatial allocation of attention during WM maintenance and that this modulation was reduced with LZP dosage.
The Decrease in Alpha Power Modulations with LZP Predicts WM Impairment Next, we investigated the modulations in alpha power by LZP in relation to WM performance. To do so, we correlated the drug-related alpha MI changes (combined over hemispheres) with the drug-related performance changes over participants (combined over hemifields). We found a positive correlation between the alpha MI reduction and the decrease in K span when comparing 0.5 mg LZP to placebo (r spearman = 0.60, p < 0.005; Figure 5F ). This was also the case when comparing placebo with 1.5 mg LZP (r spearman = 0.45, p < 0.05; Figure 5G ). To conclude, the participants with the strongest memory-related impairment were the ones with the strongest alpha MI reductions.
LZP Interacts with Alpha Power in Ipsilateral and Contralateral Hemispheres
Is the decrease in alpha MI by LZP mainly explained by alpha modulations in the hemisphere ipsilateral or contralateral to the cued hemifield? WM impairment could be a consequence of a failure to inhibit distracting visual information as reflected by ipsilateral alpha power. To investigate this issue, we computed the absolute alpha power in ipsilateral and contralateral sensors during the delay interval for all dosages separately. This revealed that the absolute alpha power during the delay interval in ipsilateral hemisphere was stronger than that in contralateral hemisphere (F 1, 24 = 35.5, p < 5 3 10 26 ; Figure 6) . Strikingly, as seen in Figure 6 , the 3 3 2 repeated-measures ANOVA revealed a significant drug 3 hemisphere interaction (F 1.6 38.4 = 6.07, p < 0.01; Figures 6D and 6E ), suggesting that LZP impacted alpha power in ipsilateral hemisphere differently compared to contralateral hemisphere. This was explained by LZP strongly reducing the alpha power in the ipsilateral hemisphere to the cued visual hemifield (ipsi placebo > ipsi 0.5 mg LZP: t 24 = 3.15, p < 0.01; ipsi placebo > ipsi10.5 mg LZP: t 24 = 6.43, p < 5 3 10 26 ; ipsi 0.5 mg LZP > ipsi 1.5 mg LZP: t 24 = 5.09, p < 10 24 ) in comparison to the contralateral power (contra placebo > contra 0.5 mg LZP: t 24 = 2.26, p < 0.05; contra placebo > contra 1.5 mg LZP: t 24 = 4.44, p < 5 3 10 24 ; contra 0.5 mg LZP > contra 1.5 mg LZP: t 24 = 5.28, p < 5 3 10 25 ; Figures 6D and 6E ). The present interaction was specific to the delay interval; it was not observed in the cue interval (F 2, 48 = 0.82, p = 0.44).
As for alpha MI, for each participant, we fitted regression lines to ipsilateral and contralateral hemispheric alpha power using categorical values to represent LZP concentrations. Both the ipsilateral (20.07 6 0.01; t 24 = 26.43, p < 5 3 10 26 ) and contralateral (20.06 6 0.01; t 24 = 25.28, p < 5 3 10 25 ) slopes were significantly different from zero. Importantly, the regression slopes were significantly more negative in sensors in the ipsilateral hemisphere compared to the contralateral hemisphere (t 24 = 22.82, p < 0.01). We also tested whether the absolute power correlated with the alpha MI over subjects; this was not the case. In addition, the individual drug-related changes in alpha MI did not correlate with the drug-related changes in absolute alpha power during the delay interval.
In sum, LZP reduced alpha power in the ipsilateral hemisphere more so than in the contralateral hemisphere during the delay interval of the WM task.
Gamma and Alpha Attentional Power Modulations Correlate over Participants
So far, we have demonstrated that gamma and alpha power are modulated as a function of spatial attention (Figures S4 and 5A-5C, respectively). Does the alpha modulation in the delay interval predict the gamma modulation during the probe delay? To test this, we correlated over participants the alpha MI during the delay interval with the gamma MI during the probe interval for each MEG session separately (using the MIs combined over hemispheres). We found a significant negative correlation during placebo (r spearman = 20.42, p < 0.05) and 1.5 mg LZP (r spearman = 20.42, p < 0.05), but not during 0.5 mg LZP (r spearman = 20.31, p = 0.13; Figure S6 ). This means that the participants with a stronger alpha power modulation during retention (positive MI) are also those with a stronger gamma power modulation in the reverse direction during probe processing (negative MI). These findings suggest that alpha band modulation reflects topdown control, which is predictive of the gamma band activity reflecting feedforward processing.
Discussion
We used MEG to investigate how the GABAergic allosteric modulator LZP influences human oscillatory brain activity during WM operations. We show for the first time in humans that stimulusinduced gamma power increases while frequency decreases due to the enhancement of inhibitory conductance by the selective enhancement of GABA A receptors. The drug-related increase in occipital gamma power contralateral to the attended hemifield was predictive of increases in response times. Even though LZP modulates GABA A receptors brain-wide, sensorimotor gamma activity was not modulated by LZP, i.e., the effect in the gamma band was specific to the visual cortex. Oscillations in the alpha band were strongly lateralized according to direction of attention during the memory delay: they decreased in occipital regions contralateral to the side of the cued memory array, whereas they increased relatively in ipsilateral regions. The alpha band lateralization was reduced with LZP dosage, and furthermore, it predicted WM performance. Our findings strongly implicate GABAergic interneurons in the regulation and generation of gamma and alpha activity, respectively, during human WM operations.
GABAergic Modulations of Gamma Oscillations
Our findings show that human visual gamma power and frequency are modulated by an increase in GABA A neurotransmission. Although previous studies have implicated GABA in generating gamma band activity associated with visual stimulation, the findings are mixed. Recent MEG studies reported a gamma power increase with the GABA A receptor agonist propofol [23] , but not with the GABA reuptaker inhibitor tiagabine [24] . The decrease in gamma frequency with LZP has not been reported in other studies applying GABAergic allosteric modulators in humans [23, 24] but has been shown in rat and monkey visual cortex under anesthesia [25, 26] . In addition, the administration of alcohol (GABA and NMDA modulator) did produce a decrease in gamma frequency during visual stimulation [27] . Finally, a recent study combining magnetic resonance spectroscopy (MRS) and MEG found a relationship between gamma frequency and GABA concentration [28] , although the reliability of the findings have been challenged very recently [29] . In our study, sensorimotor gamma power changes locked to the button press were not modulated by the drug [20, 21] . In a recent study on humans in which acetylcholine was enhanced, an effect on gamma power in visual, but not sensorimotor, regions was reported [30] . Furthermore, it should be emphasized that the concentration of GABA receptors is disproportionally high in the occipital cortex, as measured by PET [31] . We concluded that the physiological mechanisms of sensorimotor gamma activity differ from the mechanisms of visual gamma activity. As such, our findings are the first to report a robust increase in gamma band activity in a WM task associated with a frequency decrease due to GABA A enhancement.
Which mechanisms might explain the increase in gamma power and the decrease in frequency with LZP? The physiological mechanisms behind gamma oscillations have been extensively studied by in vitro work in the rat hippocampus [2, 3] . This work has demonstrated that GABAergic interneurons play a critical role for the rhythmic synchronization on neuronal populations in the gamma band. It has been demonstrated that gamma power increases as a function of IPSP ( [4] [5] [6] , but see [7] ). Also, the increases in IPSPs result in a prolongation of the gamma cycle, thus reducing the gamma frequency [4] [5] [6] [7] . Two mechanisms have been proposed for generating gamma oscillations: the interneuronal network gamma (ING) and the pyramidal-interneuronal network gamma (PING) mechanism. In ING models, inhibitory interneurons are necessary and sufficient for generating gamma oscillations [6] , whereas in PING, the gamma oscillations are a consequence of the interplay between pyramidal and inhibitory interneurons [32] . Because MEG recordings cannot tell cell types apart [33] , we cannot distinguish whether a PING or an ING mechanism dominates. However, in a recent nonhuman primate study, Vinck et al. [34] analyzed intracranially recorded single-unit activity in association with gamma oscillations in V4. They applied a spike-waveform analysis to sort the cells in broad spiking (BS) and narrow spiking (NS) neurons, i.e., putative pyramidal neurons and inhibitory cells, respectively. The firing BS neurons preceded the NS neurons by 3.3 ms while both were locked to the phase of the gamma as identified in the local field potential. This finding supports the PING model and might generalize to the human gamma band activity.
The Functional Role of Gamma Oscillations
We observed that gamma band activity was strongest contralateral to the direction of attention during visual stimulation. Previously, studies have implicated gamma oscillations in visual processing and neuronal communication [35] . For instance, it has been proposed that gamma band synchronization results in a stronger feedforward drive to downstream visual regions [36] [37] [38] . We propose that the gamma band synchronization we observed during the sample and probe intervals reflects encoding and recall of the attended memory array involving early visual areas. Importantly, the increase in gamma power with LZP does not predict better performance. We conclude that although the gamma band synchronization might reflect the encoding visual stimuli, it does not necessarily mean that more gamma power is predictive of better performance.
GABAergic Modulation of Alpha Oscillations
It is well established that alpha power recorded during rest is reduced with GABAergic agonists ( [13, 14] , but see [39, 40] ). We now extend these findings by demonstrating that the modulation of alpha power also is robustly reduced during WM maintenance. High alpha power has been proposed to reflect reduced vigilance. Because we find that LZP decreases alpha power while performance is reduced, it is clear that the magnitude of alpha power does not simply equate lack of vigilance.
What are the mechanisms explaining the decrease in alpha power with LZP? One simple explanation is that LZP increases GABAergic inhibition and reduces the pyramidal firing without affecting oscillatory frequency per se. This interpretation is consistent with an in vitro study applying diazepam: although this GABAergic agonist decreases the number of spikes per burst, it leaves the burst rate unaffected [41] . Another not mutually exclusive possibility is the involvement of the thalamus in the generation of alpha oscillations. Whereas the alpha activity measured with MEG is most likely produced by sources in the deeper layers of neocortex [42, 43] , the neocortical alpha sources have been found to be coupled to thalamic generators [12, 44, 45] . These findings have been used to constrain physiologically realistic computational models of the alpha rhythm [46] . As such, the modulation in alpha activity with LZP might have a thalamic origin as well.
Given the proposed inhibitory role of the alpha band activity [15, 16] , one might have expected the alpha power to increase as the GABAergic inhibition increases. Because we obtained the reverse finding, the dynamics are evidently more complicated than that. Future intracranial animal recordings would be required to gain full insight into this issue.
In future research, it would be interesting to uncover whether it is actually the GABAergic modulation of frontal or subcortical sources causing the changes in posterior alpha band activity. Given that it is problematic to detect deeper sources with MEG, this could be done in a combined EEG/ fMRI. Drug-specific effects in relation to the alpha activity could then be investigated in regions potentially involved in the control of the alpha activity (dorsal attention network, pulvinar, and striatum).
The Functional Role of the Alpha Band Oscillations
It has been proposed that alpha band activity reflects the allocation of computational resources [15, 16] . Basically, a regional-specific increase in alpha power reflects functional inhibition, whereas a decrease reflects engagement. This inhibition might be crucial for distracter suppression, ensuring the integrity of the WM representations [47, 48] . Our findings are fully consistent with this notion. Consistently, LZP produced a stronger reduction in alpha power suppression over ipsilateral hemisphere in comparison with the suppression in contralateral hemisphere during the delay period, not during the cue. We interpret this finding as a pharmacological task-specific effect on alpha oscillations that cannot be accounted for by a general decrease in vigilance (i.e., the same power decrease would be expected in ipsilateral and contralateral hemispheres).
Conclusions
Altogether, the results presented here suggest that the same GABAergic physiological mechanism for neuronal gamma oscillations uncovered by hippocampal rat models applies to human visual brain oscillations during WM processing. Because the modulations in the alpha band were present during the cue and delay intervals, we propose that alpha oscillations reflect top-down processing (see also [38] ). The gamma band activity mainly occurred during the presentation of the memory array and probe and is therefore likely to be dominated by feedforward processing. Our data underscore an important role of GABAergic neurotransmission for neuronal synchronization on both gamma and alpha band oscillations. As such, our findings bring us an important step closer to linking neuronal dynamics to human behavior by embracing established animal models.
Experimental Procedures
Thirty-two healthy participants gave informed consent approved by the local research ethics committee (Commissie Mensgebonden Onderzoek; Arnhem-Nijmegen, number: 2011/199, date: August 5, 2011) and were compensated for their participation. Data from seven participants were rejected (see Supplemental Experimental Procedures for rejection criteria), leaving a total of 25 participants. They were all right-handed and had normal or corrected-to-normal vision (mean age: 22.4, range: 18-28 years old, 12 males; see Supplemental Experimental Procedures and Figure 1A for complete experimental design and general pharmacological procedure).
We adapted a classical delayed match-to-sample visuospatial WM task [18] while ongoing brain activity was recorded using a whole-head MEG system with 275 axial gradiometers (VSM/CTF Systems). Data were analyzed offline using FieldTrip [49] (http://fieldtrip.fcdonders.nl/), an open-source toolbox developed at the Donders Institute for Brain, Cognition, and Behavior, and custom MATLAB code (MathWorks).
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